Insider Buying: Alphatec (NASDAQ:ATEC) Director Purchases $408,600.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Demski bought 60,000 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were purchased at an average cost of $6.81 per share, with a total value of $408,600.00. Following the acquisition, the director directly owned 491,635 shares of the company’s stock, valued at approximately $3,348,034.35. This trade represents a 13.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alphatec Trading Up 10.8%

Shares of NASDAQ ATEC opened at $8.28 on Thursday. The business’s 50 day moving average price is $10.04 and its 200 day moving average price is $10.48. Alphatec Holdings, Inc. has a 52 week low of $6.81 and a 52 week high of $23.29.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The business had revenue of $221.17 million during the quarter, compared to analyst estimates of $225.16 million. During the same quarter last year, the company posted $0.03 EPS. Alphatec’s quarterly revenue was up 12.6% compared to the same quarter last year. On average, sell-side analysts expect that Alphatec Holdings, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ATEC has been the subject of a number of research reports. Wells Fargo & Company decreased their target price on shares of Alphatec from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. BMO Capital Markets downgraded Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price target on the stock. in a research report on Friday, October 30th. JPMorgan Chase & Co. reduced their price objective on Alphatec from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Stephens began coverage on Alphatec in a report on Thursday, July 23rd. They issued an “overweight” rating and a $15.00 price objective for the company. Finally, Needham & Company LLC lowered their target price on Alphatec from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.63.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Director David Demski bought 60,000 shares for about $408,600, increasing his holdings by 13.9%. The purchase was made under a pre-arranged Rule 10b5-1 plan, so it may be less indicative of a newly formed view. Director stock purchase
• Negative Sentiment: UBS downgraded ATEC from Buy to Neutral and cut its price target to $8.50 from $15, signaling significantly reduced expectations; the new target implies limited upside from the cited recent share price. UBS downgrade
• Negative Sentiment: Alphatec’s lower 2026 revenue outlook, attributed in part to a temporary international supply constraint, has prompted securities-law investigations into whether earlier disclosures about its international business were adequate. These are investigations, not findings of wrongdoing, but add legal and reputational uncertainty. Levi & Korsinsky investigation notice
• Negative Sentiment: The company’s latest quarter also fell short of consensus for earnings and revenue, despite revenue growing 12.6% year over year. The shortfalls add to concerns following the reduced outlook.

Institutional Trading of Alphatec

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new stake in shares of Alphatec in the first quarter valued at approximately $29,000. Sterling Capital Management LLC lifted its position in shares of Alphatec by 841.5% during the 3rd quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock valued at $42,000 after buying an additional 3,669 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Alphatec in the 2nd quarter valued at $52,000. Allworth Financial LP grew its stake in Alphatec by 82.6% in the 2nd quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company’s stock valued at $58,000 after acquiring an additional 3,015 shares during the period. Finally, Chicago Partners Investment Group LLC acquired a new stake in Alphatec in the 3rd quarter valued at $112,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.